Updated Efficacy and Safety Results of the Phase 3 CANDOR study

Efficacy and safety results of a randomised controlled phase III studyПодробнее

The CANDOR trial extended follow-up: daratumumab for R/R myelomaПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study CandorПодробнее

Efficacy and safety of KdD in RRMM: Cross‐study comparison of CANDOR and MMY1001Подробнее

CANDOR results reveal new regimen for RRMM: KdDПодробнее

Safety and efficacy of once-weekly carfilzomib dosing in frail patients: Phase 3 ARROWПодробнее

KdD vs. Kd for the Treatment of Relapsed or Refractory Multiple Myeloma (Phase 3 Study Cando)Подробнее

CANDOR: KdD is a new regimen for R/R MMПодробнее

Discussion of a Phase III trial evaluating the efficacy and safety of idelalisibПодробнее

Dara-Kd shows efficacy in len-refractory cohort in latest CANDOR reportsПодробнее

What is the CANDOR trial?Подробнее

CANDOR: Triple drug combo delays disease progression in stubborn multiple myelomaПодробнее

4-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and DexamethasoneПодробнее

CANDOR study: should Dara-Kd become the new SOC for len refractory patients with RRMM?Подробнее

Real-world efficacy and safety of selinexor in R/R multiple myelomaПодробнее

Dr. Yee on the Results of the CANDOR Trial in Relapsed/Refractory MyelomaПодробнее

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapyПодробнее

Isatuximab plus carfilzomib and dex in patients with RRMM: IKEMA subgroup analysisПодробнее

Carfilzomib 2x Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and DexПодробнее